Effect of diabetes on endometrial cancer recurrence and survival

被引:27
作者
Zanders, Marjolein M. J. [1 ,2 ]
Boll, Dorry [3 ]
van Steenbergen, Liza N. [2 ]
van de Poll-Franse, Lonneke V. [2 ,4 ]
Haak, Harm R. [1 ]
机构
[1] Maxima Med Ctr, Dept Internal Med, Eindhoven, Netherlands
[2] CCCS, Eindhoven Canc Registry, NL-5600 AE Eindhoven, Netherlands
[3] Twee Steden Hosp, Dept Gynaecol, OOG IKZ, Tilburg, Netherlands
[4] Tilburg Univ, CoRPS Ctr Res Psychol Somat Dis, Dept Med Psychol, Tilburg, Netherlands
关键词
Population-based study; Cancer Registry; Diabetes mellitus; Endometrial cancer; Disease-specific Mortality; CO-MORBIDITY; CARCINOMA; RISK; POPULATION; MELLITUS; IMPACT; METAANALYSIS; ADIPONECTIN; PREVENTION; MORTALITY;
D O I
10.1016/j.maturitas.2012.10.007
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Objective: The purpose of this study was to investigate the influence of diabetes mellitus (DM) on cancer stage at diagnosis, cancer recurrence, and survival of endometrial cancer (EC) patients and the influence of the treatment of EC on glycaemic control, treatment, and complications of DM. Methods: In this retrospective cohort study all 1644 patients with EC newly diagnosed in 2000-2008 and recorded in the population-based Eindhoven Cancer Registry (ECR) were included. In addition, from this total cohort a subcohort was selected for additional data collection and analyses, including 193 EC patients with DM and an age-matched sample of 195 EC patients without DM. Patients with FIGO stage IV as well as non-endometrioid histology were excluded. Results: In the total cohort EC patients with DM had a significantly higher age (69 years vs. 64 years), higher FIGO stages and more additional comorbidities compared to EC patients without DM. The 5-year overall survival rate for EC patients with DM was significantly lower than for EC patients without DM (68% vs. 84%). After adjusting for age, stage, period of diagnosis, cardiovascular disease, and treatment, this significant effect of DM on overall mortality persisted (HR 1.4,95% CI: 1.0-1.8). Subcohort analyses showed that EC patients with DM were diagnosed more often with a higher body mass index (BMI) (34 kg/m(2) vs. 30 kg/m(2)) and EC was not significantly associated with changes in DM characteristics over time. Although the 5-year overall survival rate for EC patients with DM was significantly lower in the subcohort, for EC-specific mortality (n=388) no statistically significant effect of DM was observed after adjustment for FIGO stage (HR=1.7, 95% CI: 0.7-3.9). Conclusions: EC patients with DM compared to those without had worse patient characteristics, a higher FIGO stage, similar recurrence rates and worse overall survival. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:37 / 43
页数:7
相关论文
共 36 条
[1]  
[Anonymous], 2011, NATL DUTCH GUIDELINE
[2]  
[Anonymous], 2004, TRENDS PROGN IMPL HE
[3]  
[Anonymous], 1976, INT CLASS DIS ONC VE
[4]  
[Anonymous], 2002, Maandstatistiek Van de Bevolking
[5]  
Baan CA, 2009, 260322004 RIVM
[6]   Long-term All-Cause Mortality in Cancer Patients With Preexisting Diabetes Mellitus A Systematic Review and Meta-analysis [J].
Barone, Bethany B. ;
Yeh, Hsin-Chieh ;
Snyder, Claire F. ;
Peairs, Kimberly S. ;
Stein, Kelly B. ;
Derr, Rachel L. ;
Wolff, Antonio C. ;
Brancati, Frederick L. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (23) :2754-2764
[7]   2 PATHOGENETIC TYPES OF ENDOMETRIAL CARCINOMA [J].
BOKHMAN, JV .
GYNECOLOGIC ONCOLOGY, 1983, 15 (01) :10-17
[8]   Adherence to national guidelines for treatment and outcome of endometrial cancer stage I in relation to co-morbidity in southern Netherlands 1995-2008 [J].
Boll, D. ;
Verhoeven, R. H. A. ;
van der Aa, M. A. ;
Lybeert, M. L. M. ;
Coebergh, J. W. W. ;
Janssen-Heijnen, M. L. G. .
EUROPEAN JOURNAL OF CANCER, 2011, 47 (10) :1504-1510
[9]   Endometrial cancer incidence trends in Europe: Underlying determinants and prospects for prevention [J].
Bray, F ;
Silva, ID ;
Moller, H ;
Weiderpass, E .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (05) :1132-1142
[10]   Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy [J].
Cantrell, Leigh A. ;
Zhou, Chunxiao ;
Mendivil, Alberto ;
Malloy, Kimberly M. ;
Gehrig, Paola A. ;
Bae-Jump, Victoria L. .
GYNECOLOGIC ONCOLOGY, 2010, 116 (01) :92-98